Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 25%Moderate 6 · 75%High 0 · 0%

Sclerotherapy (STS) vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy (STS) probably leads to higher adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 1.71 [1.1, 2.64]
4 studies · 478 participants
Moderate

Sclerotherapy vs placebo

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy probably leads to higher adverse events ‐ hyperpigmentation ( compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 11.88 [4.54, 31.09]
3 studies · 528 participants
Moderate

Laser plus sclerotherapy vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Laser plus sclerotherapy showed no clear difference in adverse events ‐ Hyperpigmentation ( compared with sclerotherapy (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.83 [0.35, 1.99]
2 studies · 656 participants
Low

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy (polidocanol) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.94 [0.62, 1.43]
6 studies · 819 participants
Moderate

Sclerotherapy plus compression vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy plus compression showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy alone (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.93 [0.41, 2.07]
2 studies · 196 participants
Moderate

Sclerotherapy (hypertonic saline) vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy (hypertonic saline) probably leads to lower adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.74 [0.59, 0.93]
2 studies · 288 participants
Moderate

Sclerotherapy (chromated glycerin) vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy (chromated glycerin) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (low certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.49 [0.09, 2.5]
2 studies · 125 participants
Low

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.79 [0.62, 1.01]
2 studies · 191 participants
Moderate